Kestra Medical Technologies Ltd. stock kpis
Want to see KMTS full AI Analyst Report?
Prescriptions For Assure System
Kestra Medical Technologies Ltd. reported prescriptions for assure system of 6,357 in Q4 FY2026, up 16.4% from Q3 FY2026 and up 62.9% year over year. This is the highest value since 2025.
Indicates the number of prescriptions written for the Assure System, highlighting the product's market acceptance and potential revenue growth as more healthcare providers adopt this technology.
Prescriptions show accelerating momentum late in the period—an inflection consistent with management’s cited drivers: higher in‑network penetration, improving conversion and expanding sales territories—which together lift both volume and revenue-per-fit. The January jump likely reflects seasonality (deductible resets) layered on this structural ramp and recent payer wins/FDA progress, but beware that rapid territory scale-up and the long payer tail increase execution and cash-burn risk if new reps underperform or contracting lags.
KMTS Prescriptions For Assure System
| Period | Prescriptions For Assure System |
|---|---|
| Q4 FY2026Apr 30, 2026 | 6,357 |
| Q3 FY2026Jan 31, 2026 | 5,462 |
| Q2 FY2026Oct 31, 2025 | 4,696 |
| Q1 FY2026Jul 31, 2025 | 4,205 |
| Q4 FY2025Apr 30, 2025 | 3,902 |
| Q3 FY2025Jan 31, 2025 | 3,459 |

